New approaches to anti-inflammatory therapy for asthma

American Journal of Medicine

Volumn 104, Issue 3, 1998, Pages 287-300

  Wenzel, Sally E ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; FLUNISOLIDE; FLUTICASONE; GOLD; IMMUNOGLOBULIN G; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; METHYLPREDNISOLONE; NEDOCROMIL; PREDNISONE; TRIAMCINOLONE; ZAFIRLUKAST; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CORTICOSTEROID THERAPY; INFLAMMATION; METERED DOSE INHALER; PRIORITY JOURNAL; REVIEW;

ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; DICARBOXYLIC ACIDS; HUMANS; HYDROXYUREA; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; STEROIDS; TOSYL COMPOUNDS;

EID: 0032033704     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00031-X     Document Type: Review

References (100)

1. 1. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992;256:669-674.
2. 2. Robinson D, Hamid Q, Ying S, et al. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar ravage cell interleukin-4, interleukin-5, and interferon-γ cytokine gene expression. Am Rev Respir Dis. 1993;148:401-406.
3. 3. Wang JH, Trigg CJ, Devalia JL, et al. Effect of inhaled beclomethasone dipropionate on expression of proinflammatory cytokines and activated eosinophils in the bronchial epithelium of patients with mild asthma. J Allergy Clin Immunol. 1994;94:1025-1034.
4. 4. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by corticosteroids. Science. 1995;270:283-286.
5. 5. Wallner BP, Mattaliano RJ, Hession C, et al. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature. 1986;320:77-81.
6. 6. Northup JK, Valentine-Braun KA, Johnson LK, et al. Evaluation of the anti-inflammatory and phospholipase-inhibitory activity of calpactin II/lipocortin I. J Clin Invest. 1988;82:1347-1352.
7. 7. Pouliot M, McDonald PP, Borgeat P, McColl SR. Granulocyte/ macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils. J Exp Med. 1994;179:1225-1232.
8. 8. Samet JM, Fasano MB, Fonteh A, Chilton FH. Selective induction of prostaglandin G/H synthase I by stem cell factor and dexamethasone in mast cells. J Biol Chem. 1995;270:8044-8049.
9. 9. Dahl R, Johansson S-A. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. Eur Respir J. 1982;63(suppl 122):167-175.
10. 10. O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis. 1993;147:1472-1476.
11. 11. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 1994;149:953-959.
12. 12. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224.
13. 13. Hummel S, Lehtonen L. Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma. Lancet. 1992;340:1483-1487.
14. 14. Boe J, Bakke P, Rodolen T, et al. High dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J. 1994;7:2179-2184.
15. 15. Dahl R, Lundback B, Malo J-L, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest. 1993;104:1352-1358.
16. 16. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol. 1994;94:676-683.
17. 17. Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax. 1993;48:817-823.
18. 18. Waalkens HJ, Van Essen-Zandvliet EE, Hughes MD, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis. 1993;148:1252-1257.
19. 19. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. NEJM. 1994;331:700-705.
20. 20. Booth H, Richmond I, Ward C, et al. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. J Clin Endocrinol Metab. 1995;80:1243-1246.
21. 21. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med. 1994;154:1349-1352.
22. 22. Kerstjens HAM, Postma DS, van Doormaal JJ, et al. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Thorax. 1994;49:652-656.
23. 23. Hanania NA, Chapman KR, Sturtridge WC, et al. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995;96(5 pt 1): 571-579.
24. 24. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150:11-16.
25. 25. Landwehr LP, Spahn JD, Szefler SJ, Leung DYM. Management of steroid-resistant asthma. Clin Immunother. 1995;4:124-137.
26. 26. Cypcar D, Busse WW. Steroid-resistant asthma. J Allergy Clin Immunol. 1993;92:362-372.
27. 27. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 1996;97:169-176.
28. 28. Landwehr L, Spahn J, Kamada A, et al. Effects of hydrocortisone vs. synthetic glucocorticoids on lymphocyte activation in steroid resistant (SR) asthmatics. J Allergy Clin Immunol. 1995;95(1 pt 2):A387. Abstract.
29. 29. Lundback B, Alexander M, Day J, et al. Evaluation of fluticasone propionate (500 μg/day) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1,000 μg/day) administered by pressurized inhaler. Respir Med. 1993;87:609-620.
30. 30. Ayres J, Bateman E, Lundback B, Harris T. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J. 1995;8:579-586.
31. 31. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med. 1995;152(5 pt 1):1467-1473.
32. 32. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996;51:262-266.
33. 33. Todd G, Dunlop K, McNaboe J, et al. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet. 1996;348(9029):27-29.
34. 34. Boe J, Bakke P, Rodolen T, et al. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J. 1994;7:2179-2184.
35. 35. Pincus DJ, Szefler SJ, Ackerson LM, Martin RJ. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol. 1995;95:1172-1178.
36. 36. Gagnon M, Cote J, Milot J, et al. Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma. Chest. 1994;105:1732-1737.
37. 37. Sullivan P, Bekir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet. 1994;343: 1006-1008.
38. 38. Djukanovic R, Finnerty J, Lee C, et al. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J. 1995;8:831-833.
39. 39. Pelikan Z, Knottnerus I. Clinical aspects of allergic disease: inhibition of the late asthmatic response by nedocromil sodium administered more than two hours after allergen challenge. J Allergy Clin Immunol. 1993;92:19-28.
40. 40. Lal S, Dorow PD, Venho KK, Chatterjee SS. Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease. Chest. 1993;104:438-447.
41. 41. Bel EH, Timmers MC, Hermans J, et al. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis. 1990;141:21-28.
42. 42. Svendsen UG, Jorgensen H. Inhaled nedocromil sodium as additional treatment to high dose inhaled corticosteroids in the management of bronchial asthma. Eur Respir J. 1991;4:992-999.
43. 43. Mullarkey MF, Blumenstein BA, Andrade WP, et al. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study. NEJM. 1988;318:603-607.
44. 44. Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet. 1990;336:137-140.
45. 45. Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol. 1991;88: 208-212.
46. 46. Erzurum SC, Leff JA, Cochran JE, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. Ann Intern Med. 1991;114:353-360.
47. 47. Taylor DR, Flannery EM, Herbison GP. Methotrexate in the management of severe steroid dependent asthma. NZ Med J. 1993;106: 409-411.
48. 48. Trigg CJ, Davies RJ. Comparison of methotrexate 30 mg per week with placebo in chronic steroid-dependent asthma: a 12-week double-blind, cross-over study. Respir Med. 1993;87:211-216.
49. 49. Coffey MJ, Sanders G, Eschenbacher WL, et al. The role of methotrexate in the management of steroid-dependent asthma. Chest. 1994;105:117-121.
50. 50. Stewart GE, Diaz JD, Lockey RF, et al. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma. J Allergy Clin Immunol. 1994;94(3 pt 1):482-489.
51. 51. Tsai JJ, Shin JF, Chen CH, Wang SR. Methotrexate pneumonitis in bronchial asthma. Int Arch Allergy Immunol. 1993;100:287-290.
52. 52. Elwood W, Lotvall JO, Barnes PJ, Chung KF. Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. Am Rev Respir Dis. 1992;145:1289-1294.
53. 53. Naora H, Young IG. Comparison of the mechanisms regulating IL-5, IL-4, and three other lymphokine genes in the Th2 clone. Exp Hematol. 1995;23:597-602.
54. 54. Corrigan CJ, Brown PH, Barnes NC, et al. Glucocorticoid resistance in chronic asthma. Am Rev Respir Dis. 1991;144:1026-1032.
55. 55. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet. 1992;339: 324-328.
56. 56. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med. 1996; 153:509-514.
57. 57. Nierop G, Gijzel WP, Bel EH, et al. Auranofin in the treatment of steroid dependent asthma: a double blind study. Thorax. 1992;47: 349-354.
58. 58. Bernstein IL, Bernstein DI, Dubb JW, et al. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. J Allergy Clin Immunol. 1996; 98:317-324.
59. 59. Honma M, Tamura G, Shirato H, Trakishima T. The effect of oral gold compound, auranofin, on nonspecific bronchial hyperresponsiveness in mild asthma. Thorax. 1994;49:649-651.
60. 60. Pauwels R, Joos G, Kips J. Leukotrienes as therapeutic target in asthma. Allergy. 1995;60:615-622.
61. 61. Lewis RA, Austen F, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. NEJM. 1990;323:645-655.
62. 62. Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341: 989-990.
63. 63. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy. 1997;17(1 pt 2):3S-12S.
64. 64. Drazen JM. Leukotrienes. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Oxford: Blackwell Scientific; 1995:838-850.
65. 65. Wenzel SE, Fowler AAI, Schwartz LB. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. Am Rev Resp Dis. 1988;137:1002-1008.
66. 66. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperactivity in atopic subjects. Lancet. 1991;337:690-694.
67. 67. Rasmussen J, Eriksson LO, Margolskee D, et al. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstriction responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992;90:193-201.
68. 68. Nathan R, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (Accolate) or cromolyn sodium (Intal) in patients with mild to moderate asthma. J Allergy Clin Immunol. 1995;95: A388. Abstract.
69. 69. Dahlén B, Kumlin M, Margolskee D. The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine aspirin-sensitive asthmatics. Eur Respir J. 1993;6: 1018-1026.
70. 70. Christie P, Smith C, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353 inhibits aspirin induced asthma. Am Rev Respir Dis. 1991;144:957-958.
71. 71. Finnerty J, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma inhibitory effect of ICI 204,219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992;145(4 pt 1):746-749.
72. 72. Robuschi M, Riva E, Fuccella L, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). Am Rev Respir Dis. 1992;145:1285-1288.
73. 73. Manning PJ, Watson RM, Margolskee DJ, et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potential leukotriene D4-receptor antagonist. NEJM. 1990;323:1736-1739.
74. 2)-induced bronchoconstriction in patients with mild-to-moderate asthma. Allergy. 1995;50: 45. Abstract.
75. 75. Calhoun W, Lavins B, Glass M. Effect of Accolate (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma. Am J Respir Crit Care Med. 1995;151(4 pt 2):A42. Abstract.
76. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 1992;146: 358-363.
77. 77. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991;337:1062-1063.
78. 78. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med. 1994; 150:618-623.
79. 79. Barnes N, Pujet J. First clinical experience of the oral leukotriene antagonist, pranlukast (SB205312/ONO 1078) in N. European patients with mild to moderate asthma. Am J Respir Crit Care Med. 1995;151:A378. Abstract.
80. 4 receptor antagonist, improves the signs and symptoms of asthma with a dose as low as 10 mg, once daily. Am J Respir Crit Care Med. 1995;151:A378. Abstract.
81. 81. Spector S, Miller C, Glass M. 13-week dose-response study with Accolate (zafirlukast) in patients with mild to moderate asthma. Am J Respir Crit Care Med. 1995;151:A379. Abstract.
82. 82. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:177-183.
83. 83. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148:1447-1451.
84. 84. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol. 1994;94:1046-1056.
85. 85. Wenzel SE, Trudeau JB, Kaminsky DA, et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med. 1995;152: 897-905.
86. 86. Israel E, Rubin P, Kemp J, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993;119:1059-1066.
87. 87. Liu MC, Dube LM, Lancaster J, et al. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996;98:859-871.
88. 88. Dahlen S, Nizankowska E, Dahlen B, et al. The Swedish-Polish treatment study with the 5-lipoxygenase inhibitor zileuton in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1995;151: A376. Abstract.
89. 89. O'Connor BJ, Godard P, Dube LM, et al. The comparative effect of zileuton, a 5-lipoxygenase inhibitor, plus low dose inhaled beclomethasone vs higher dose beclomethasone for asthma. J Allergy Clin Immunol. 1996;97(1 pt 3):250(A271). Abstract.
90. 90. Lazarus SC, Lee TM, Wright S, et al. Secondary outcomes analysis of zileuton plus usual care vs. usual care alone in the treatment of patients with asthma. Ann Allergy Asthma Immunol. 1997;78:94. Abstract.
91. 91. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993;147:839-844.
92. 92. Du Buske LM, Grossman J, Carpentier PJ, et al. The effect of reducing zileuton 600 mg QID in patients with moderate asthma. Ann Allergy Asthma Immunol. 1997;78:113. Abstract.
93. 93. O'Connor B, Evans D, Coulby L, Cluzel M. Treatment with a PAF receptor antagonist, SR 27417A, inhibits the late asthmatic response. Asthma Theory to Treatment: A joint conference sponsored by the American Academy of Allergy, Asthma, and Immunology and the American Thoracic Society, Chicago, Illinois, 1995.
94. 94. Melillo E, Woolley KL, Manning PJ, et al. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med. 1994;149:1138-1141.
95. 95. Pavord ID, Wong CS, Williams J, Tattersfield AK. Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis. 1993;148:87-90.
96. 4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1996;153: 572-575.
97. 97. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med. 1996;153:567-571.
98. 98. Feldsien D, Sloan S, Wenzel S. Misoprostol, a PGE1 analog, improves the physiologic and inflammatory changes of nocturnal asthma. J Allergy Clin Immunol. 1996;97(1 pt 3):A687. Abstract.
99. 99. Hanifin J, Schneider L, Leung D, et al. Recombinant interferon-γ therapy for atopic dermatitis. J Am Acad Dermatol. 1993;28(2 pt 1):189-197.
100. 100. Banner K, Marchini F, Buschi A, et al. The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. Pulmon Pharmacol. 1995;8:37-42.